Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell DiseaseJuly 18, 2018 Read More
Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of DiverticulosisJuly 11, 2018 Read More
Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc.June 19, 2018 Read More
Emmaus Life Sciences Announces Opening of Office in New York to Support Endari LaunchMarch 26, 2018 Read More
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine)March 12, 2018 Read More
